Prediction of Erectile Function Following Treatment for Prostate Cancer

Mehrdad Alemozaffar, MD
Meredith M. Regan, ScD
Matthew R. Cooperberg, MD, MPH
John T. Wei, MD
Jeff M. Michalski, MD
Howard M. Sandler, MD
Larry Hembroff, PhD
Christopher S. Saigal, MD, MPH
Eric Klein, MD
Adam S. Kibel, MD
Daniel A. Hamstra, MD
Louis L. Pisters, MD
Deborah A. Kuban, MD
Irving D. Kaplan, MD
David P. Wood, MD
Jay Ciezki, MD
Rodney L. Dunn, MS
Peter R. Carroll, MD, MPH
Martin G. Sanda, MD

Because most patients survive early-stage prostate cancer after treatment, health-related quality of life (HRQOL) outcomes have emerged as a major emphasis in treatment decisions. Erectile dysfunction is commonplace after prostate cancer treatment and has significant consequences for HRQOL. Among urinary, bowel, vitality, and sexual HRQOL domains—outcomes commonly impaired by prostate cancer treatment—sexual function in previously potent men is the most commonly impaired and is closely related to outcome satisfaction. Individual characteristics, such as pretreatment erectile function, that influence posttreatment sexual outcome are known to vary at diagnosis, yet tools to predict posttreatment erectile dysfunction based on pretreatment sexual HRQOL at baseline have been limited. Treatment refinements...
such as nerve-sparing techniques, can mitigate erectile dysfunction consequences of prostate cancer treatment, while other treatment variations, such as use of neoadjuvant hormone therapy, can adversely affect sexual outcome. Although associations of these and other factors with patient-reported sexual outcome have been studied, information regarding how the combination of pretreatment patient characteristics and treatment factors relate to individualized sexual outcome remains limited.

We sought to determine whether an individual man’s sexual outcomes after the most common treatments for early-stage prostate cancer (radical prostatectomy, external radiotherapy, or brachytherapy) can be predicted accurately based on baseline characteristics and treatment planning details.

METHODS

Study Patients and Measures

The Prostate Cancer Outcomes and Satisfaction With Treatment Quality Assessment (PROSTQA) is a prospective, longitudinal, multicenter cohort comprising men with previously untreated clinical stage T1 to T2 prostate cancer who had elected prostatectomy, external beam radiotherapy, or brachytherapy as primary treatment and were enrolled from 2003 to 2006 at 9 US university-affiliated hospitals into an institutional review board–approved protocol after providing written informed consent.

Patient demographic, race/ethnicity, and clinical data were collected (because such factors have known associations with prostate cancer aggressiveness) by research coordinators via direct patient contact, eg, clinical visits supplemented by medical record review. Details of treatment, such as plan for nerve sparing during prostatectomy or neoadjuvant hormone therapy with radiation, were collected prior to treatment to enable predictive models based on pretreatment information. Patient-reported outcome measures, including the Expanded Prostate Cancer Index Composite (EPIC-26) and information regarding use of medications or devices for erectile dysfunction, were collected by third-party telephone interview before treatment and at 2, 6, 12, and 24 months after treatment; men who completed a pretreatment evaluation (1201/1371 eligible patients who had agreed to be contacted) comprised the PROSTQA cohort.

Among the 1201 men registered for follow-up, 1027 (86%) completed the 24-month interview and are the focus of this study. Their primary treatment included either prostatectomy (n=524), external beam radiotherapy (n=241), or brachytherapy (n=262).

Statistical Analysis

Having functional erections suitable for intercourse was defined as the patient selecting the response option of “firm enough for intercourse” to the EPIC-26 question, “How would you describe the usual quality of your erections during the last 4 weeks?” (other responses indicated erectile dysfunction). Erectile function 2 years after treatment was modeled separately, according to planned treatment, using logistic regression. The pretreatment patient and disease characteristics as well as planned treatment details considered are summarized in eTable 1, available at http://www.jama.com.

Multivariable model development used a backward elimination selection procedure with 2-sided \( \alpha = .05 \). Model selection was internally validated using bootstrap resampling (500 resamples), and bootstrap estimates of parameter estimates, standard errors, pointwise 95% confidence intervals for model-predicted probabilities, and area under the receiver operating characteristic curve (AUC) were also obtained for each final model. Individual predicted probabilities of functional erections at 2 years were calculated using the inverse logistic function \( \{ \exp[X'\beta]/[1 + \exp(X'\beta)] \} \), where \( X'\beta \) is the sum with \( X \) representing individual characteristics observed and \( \beta \) representing the associated log odds ratios for the individual characteristics estimated from the model.

The omission of 2-year nonrespondents from model development assumes data are missing completely at random. A sensitivity analysis assessed the effect of this assumption by refitting each final model using a model weighted for inverse probability of response; the probability of response was estimated using multivariable logistic regression including factors associated with nonresponse (education level, number of comorbid conditions, race, and pretreatment sexual functioning [eTable 1]). This approach had little effect on the estimates, and results were not reported.

Use of medications or devices to assist erection function as measured by patient self-report at 2 years was summarized overall and in detail among the subset of 694 men who were potent (ie, reported functional erections) before treatment, excluding patients with implanted erectile aid devices.

All analyses were performed using SAS version 9.1 (SAS Institute Inc, Cary, North Carolina).

External Validation

The community-based Cancer of the Prostate Strategic Urologic Research Endeavor the CaPSURE cohort registry served as an external validation cohort for the developed models. Men in the CaPSURE cohort reported HRQOL at baseline and every 6 months in follow-up; sexual function and bother (severity and impact of patient-reported erectile dysfunction) were determined from the UCLA Prostate Cancer Index (UCLA-PCI), the instrument from which the EPIC-26 was previously derived and from which it retained 6 items. Characteristics of the CaPSURE cohort have been previously described.

Of the 1913 CaPSURE patients who completed pretreatment and 2 years posttreatment evaluation of sexual HRQOL using the UCLA-PCI, 1655 had data for all available model covariates available for validation. The PROSTQA model-predicted probabil
PREDICTING ERECTILE FUNCTION AFTER PROSTATE CANCER

RESULTS

Pretreatment patient characteristics and planned treatment details for the 1027 PROSTQA cohort patients who completed HRQOL interviews at 2 years’ follow-up are summarized in eTable 1. In the PROSTQA cohort used for predictive model development and excluding men with unknown erection quality, erectile dysfunction was reported by 274 of 983 (28% [95% CI, 25%-31%]) men prior to treatment (86/510 [17% [95% CI, 14%-20%]] in the prostatectomy group, 107/228 [47% [95% CI, 40%-54%]] in the external radiotherapy group, 81/245 [33% [95% CI, 27%-39%]] in the brachytherapy group) (eTable 2). At 2 years after treatment, erectile dysfunction was reported by 619 of 987 (63% [95% CI, 60%-66%]) men (334/511 [65% [95% CI, 61%-69%]] in the prostatectomy group, 145/229 [63% [95% CI, 57%-70%]] in the external radiotherapy group, and 140/247 [57% [95% CI, 50%-63%]] in the brachytherapy group) (eTable 2) and in 358 of 693 (52% [95% CI, 48%-55%]) men who were potent prior to treatment (248/414 [60% [95% CI, 55%-65%]] in the prostatectomy group, 51/121 [42% [95% CI, 33%-51%]] in the external radiotherapy group, 59/158 [37% [95% CI, 30%-45%]] in the brachytherapy group).

Probability of Functional Erections After Prostatectomy

The ability to attain functional erections suitable for intercourse at 2 years after treatment was reported among 177 of 511 (35% [95% CI, 30%-39%]) men who underwent prostatectomy. In univariable analyses, younger age, fewer comorbid conditions, lower prostate-specific antigen (PSA) level, lower cancer severity/risk category, pretreatment potency, better (higher) pretreatment EPIC-26 sexual HRQOL score, better (lower) pretreatment American Urological Association Symptom Index, and plan for nerve-sparing surgical technique were associated with greater probability of attaining functional erections at 2 years (each P < .05) (eTable 3); association of prostate size with sexual outcome was not statistically significant (P = .07).

In multivariable analysis, younger age, lower PSA level, better pretreatment sexual functioning score, and nerve-sparing surgery were associated with increased log-odds of functional erections (each P < .05; AUC, 0.77 [95% CI, 0.72-0.82]) (Table 1). The log-odds of erectile function increased approximately linearly with decreasing age and with increasing pretreatment sexual functioning score.

Model-predicted probabilities of functional erections after prostatectomy based on selected pretreatment sexual HRQOL scores are summarized in Figure 1 and Table 2. For example, a 50-year-old man’s prospects for having functional erections after prostatectomy vary, as tabulated, from 6% (95% CI, 2%-18%) to 70% (95% CI, 61%-77%) depending on pretreatment sexual HRQOL score, plan for nerve-sparing surgery, and sexual HRQOL score.

Table 1. Multivariable Logistic Regression Models Predicting Functional Erections Suitable for Intercourse at 2 Years After Treatment, According to Planned Primary Prostate Cancer Treatment in the PROSTQA Cohort

<table>
<thead>
<tr>
<th>Treatment, Variable</th>
<th>Parameter Estimate (SE)</th>
<th>OR (95% CI)</th>
<th>Wald χ² P Value</th>
<th>Bootstrap Parameter Estimate (SE)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prostatectomy Intercept</td>
<td>-2.96 (1.38)</td>
<td>0.05 (0.36)</td>
<td>2.3 (1.2-4.7)</td>
<td>.02 0.88 (0.37)</td>
</tr>
<tr>
<td>Pretreatment sexual HRQOL score (per 10 points)</td>
<td>0.45 (0.07)</td>
<td>1.6 (1.4-1.8)</td>
<td>.001 0.45 (0.07)</td>
<td></td>
</tr>
<tr>
<td>Age (per 10 y)</td>
<td>-0.56 (0.16)</td>
<td>0.6 (0.4-0.8)</td>
<td>.001 0.58 (0.16)</td>
<td></td>
</tr>
<tr>
<td>Nerve-sparing</td>
<td>1.29 (0.52)</td>
<td>3.6 (1.3-10.1)</td>
<td>.01 1.39 (0.57)</td>
<td></td>
</tr>
<tr>
<td>PSA ≤10 ng/mL</td>
<td>0.85 (0.36)</td>
<td>2.3 (1.2-4.7)</td>
<td>.02 0.88 (0.37)</td>
<td></td>
</tr>
<tr>
<td>External radiotherapy Intercept</td>
<td>-5.22 (0.76)</td>
<td>-5.3 (0.79)</td>
<td>-5.3 (0.79)</td>
<td></td>
</tr>
<tr>
<td>Pretreatment sexual HRQOL score (per 10 points)</td>
<td>0.54 (0.08)</td>
<td>1.7 (1.4-2.0)</td>
<td>.001 0.55 (0.09)</td>
<td></td>
</tr>
<tr>
<td>No neoadjuvant hormone therapy</td>
<td>1.18 (0.39)</td>
<td>3.3 (1.5-7.0)</td>
<td>.003 1.24 (0.41)</td>
<td></td>
</tr>
<tr>
<td>PSA ≤4 ng/mL</td>
<td>1.17 (0.46)</td>
<td>3.2 (1.3-8.0)</td>
<td>.01 1.24 (0.48)</td>
<td></td>
</tr>
<tr>
<td>Brachytherapy Intercept</td>
<td>-3.13 (2.21)</td>
<td>-3.4 (2.34)</td>
<td>-3.4 (2.34)</td>
<td></td>
</tr>
<tr>
<td>Pretreatment sexual HRQOL score (per 10 points)</td>
<td>0.72 (0.11)</td>
<td>2.1 (1.7-2.5)</td>
<td>.001 0.75 (0.11)</td>
<td></td>
</tr>
<tr>
<td>Age (per 10 y)</td>
<td>-0.63 (0.28)</td>
<td>0.5 (0.3-0.9)</td>
<td>.03 -0.64 (0.30)</td>
<td></td>
</tr>
<tr>
<td>African American race/ethnicity</td>
<td>1.13 (0.00)</td>
<td>3.1 (0.9-10.0)</td>
<td>.06 1.18 (0.64)</td>
<td></td>
</tr>
<tr>
<td>BMI&lt;sup&gt;a&lt;/sup&gt;</td>
<td>&lt;25</td>
<td>2.22 (0.86)</td>
<td>9.2 (1.7-50.0)</td>
<td>.01 2.30 (0.94)</td>
</tr>
<tr>
<td>25-34.9</td>
<td>1.40 (0.77)</td>
<td>4.0 (0.9-18.4)</td>
<td>.07 1.45 (0.85)</td>
<td></td>
</tr>
<tr>
<td>≥35</td>
<td>0</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: BMI, body mass index; CI, confidence interval; HRQOL, health-related quality of life; OR, odds ratio; PROSTQA, Prostate Cancer Outcomes and Satisfaction With Treatment Quality Assessment; PSA, prostate-specific antigen.

<sup>a</sup>Model areas under the receiver operating characteristic curve were 0.77 (95% CI, 0.72-0.82) for prostatectomy, 0.83 (95% CI, 0.78-0.88) for external radiotherapy, and 0.89 (95% CI, 0.85-0.94) for brachytherapy. Individual predicted probabilities of functional erections suitable for intercourse at 2 years can be calculated using the inverse logistic function \( \exp[Xβ]/[1 + \exp[Xβ]] \), where X is the sum with X representing individual characteristics observed and β representing the associated model parameter estimates for the individual characteristics.

<sup>b</sup>Calculated as weight in kilograms divided by height in meters squared.

©2011 American Medical Association. All rights reserved.

JAMA, September 21, 2011—Vol 306, No. 11
Corrected on September 20, 2011

1207

Downloaded From: https://jama.jamanetwork.com/ by a Non-Human Traffic (NHT) User on 03/14/2019
nerve-sparing technique, and pretreatment serum PSA level (Table 2).

**Probability of Functional Erections After External Radiotherapy**

The ability to attain functional erections suitable for intercourse at 2 years after treatment was reported among 84 of 229 (37% [95% CI, 30%-43%]) men who opted for external radiotherapy as their primary therapy. In univariable analyses, younger age, lower PSA level, lower risk category, better pretreatment sexual functioning score, better pretreatment American Urological Association Symptom Index, and no use of neoadjuvant hormone therapy were associated with greater probability of functional erections 2 years after treatment (each P < .05) (eTable 3).

In multivariable analysis, lower PSA level, better pretreatment sexual functioning score, and no use of neoadjuvant hormone therapy were associated with increased log-odds of functional erections after treatment (each P < .05; AUC, 0.83 [95% CI, 0.78-0.88]) (Table 1). The log-odds of functional erections increased approximately linearly with increasing pretreatment sexual HRQOL score.

Model-predicted probabilities of functional erections after external radiotherapy at selected pretreatment sexual HRQOL scores are summarized in Figure 2 and Table 3. A man’s predicted probability of having functional erections after external radiotherapy varies from 16% (95% CI, 9%-28%) to 92% (95% CI, 81%-97%) depending on pretreatment sexual HRQOL score, use of neoadjuvant hormone therapy, and pretreatment serum PSA level (Table 3).

**Probability of Functional Erections After Brachytherapy**

The ability to attain functional erections suitable for intercourse at 2 years...
was reported among 107 of 247 (43% [95% CI, 37%-50%]) men who opted for brachytherapy as primary treatment. In univariable analyses, younger age, college graduate, fewer comorbid conditions, and better pretreatment sexual HRQOL score were associated with greater probability of functional erections 2 years after treatment (each P < .05) (eTable 3).

In multivariable analysis, better pretreatment sexual HRQOL score, younger age, African American race/ethnicity, and lower body mass index were associated with increased log-odds of better erectile function (each P < .05; AUC = 0.89 [95% CI, 0.85-0.94]) (Table 1). The log-odds of erectile function 2 years after treatment increased approximately linearly with increasing pretreatment sexual HRQOL score and decreased approximately linearly with increasing age.

Model-predicted probabilities of functional erections after brachytherapy at selected pretreatment sexual HRQOL scores are summarized in Figure 3 and Table 4. Consequently, a 60-year-old man’s probability for having functional erections varies from 11% [95% CI, 3%-37%] to 98% [95% CI, 89%-99%] depending on pretreatment sexual HRQOL score, age, race/ethnicity, and BMI (Table 4).

**Validation of the Predictive Models in a Community-Based Cohort**

To assess the generalizability of these models for predicting erectile function after primary prostate cancer treatment, we evaluated the performance of these models in a separate cohort of 1913 men who underwent prostatectomy, external radiotherapy, or brachytherapy in the community setting and whose HRQOL had been measured via their participation in the CaPSURE registry (eTable 4).9,20,21 The CaPSURE cohort reported higher pretreatment and posttreatment erectile dysfunction (42% [95% CI, 40%-44%] and 78% [95% CI, 76%-80%] of men, respectively).

The PROSTQA models performed well in predicting functional erections suitable for intercourse 2 years after treatment, with AUCs of 0.77 (95% CI, 0.74-0.80) for men undergoing prostatectomy, 0.87 (95% CI, 0.80-0.94) for those undergoing external radiotherapy, and 0.90 (95% CI, 0.85-0.95) for those undergoing brachytherapy. Calibration showed that model-predicted probabilities of functional erections corresponded to the observed outcome in the CaPSURE cohort (Table 5).

**Use of Medications or Devices for Erectile Dysfunction**

Prior to treatment, 6 men reported having a penile prosthesis (5 prostatectomy, 1 brachytherapy); among all other men, 269 of 1014 (27% [95% CI, 24%-29%]) reported having used medications or devices for erectile dysfunction (26% [95% CI, 22%-30%] in the prostatectomy group, 23% [95% CI, 18%-29%] in the external radiotherapy group, 31% [95% CI, 25%-37%] in the brachytherapy group). At 2 years, 14 men (9 prostatectomy, 1 external radiotherapy, 4 brachytherapy) reported having a penile prosthesis, and 53% [95% CI, 50%-56%] of all other men reported having used medications or devices for erectile dysfunction (66% [95% CI, 61%-70%] prostatectomy, 32% [95% CI, 26%-38%] external radiotherapy, 47% [95% CI, 41%-53%] brachytherapy), and 61% (95% CI, 57%-64%) of men who were potent prior to treatment reported having used any such aids at 2 years (69% [95% CI, 65%-74%] prostatectomy, 40% [95% CI, 31%-49%] external radiotherapy).

**Figure 2. Model-Predicted Probability of Functional Erections Suitable for Intercourse 2 Years After External Radiotherapy for Prostate Cancer**

Model-predicted probabilities based on pretreatment Expanded Prostate Cancer Index Composite sexual function score stratified by pretreatment prostate-specific antigen (PSA) level and planned use of neoadjuvant hormone therapy. Higher sexual function score denotes better sexual function. N=241 (39 [16%] with PSA level <4 ng/mL and 74 [31%] receiving neoadjuvant hormone therapy.

**Table 3. PROSTQA Model−Predicted Probabilities of Men Having Functional Erections Suitable for Intercourse 2 Years After External Radiotherapy for Prostate Cancer**

<table>
<thead>
<tr>
<th>Planned Neoadjuvant Hormone Therapy</th>
<th>Pretreatment PSA Level, ng/mL</th>
<th>Predicted Functional Erections After Treatment, % (95% CI) (by Pretreatment Sexual HRQOL Score)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>67</td>
<td>83</td>
</tr>
<tr>
<td>No</td>
<td>≥4</td>
<td>92 (81-97)</td>
</tr>
<tr>
<td></td>
<td>&lt;4</td>
<td>79 (67-87)</td>
</tr>
<tr>
<td>Yes</td>
<td>≥4</td>
<td>79 (55-92)</td>
</tr>
<tr>
<td></td>
<td>&lt;4</td>
<td>53 (35-71)</td>
</tr>
</tbody>
</table>

Abbreviations: HRQOL, health-related quality of life; PROSTQA, Prostate Cancer Outcomes and Satisfaction With Treatment Quality Assessment; PSA, prostate-specific antigen.

Individual model-predicted probabilities were calculated using the inverse logistic function \(\exp(X'\beta)/[1 + \exp(X'\beta)]\), where \(X'\) is the sum with \(X\) representing individual characteristics observed and \(\beta\) representing the associated model parameter estimates for the individual characteristics in Table 1.

©2011 American Medical Association. All rights reserved.
Abbreviations: BMI, body mass index; HRQOL, health-related quality of life; PROSTQA, Prostate Cancer Outcomes and Satisfaction With Treatment Quality Assessment.

White race/ethnicity included 3% of patients of other (non–African American) race. Higher sexual function score denotes better sexual function. N=262 (28 [11%] African American; 57 [22%] with BMI <25, 187 [71%] with BMI 25-35, and 18 [7%] with BMI ≥35; median age, 66 years.

Table 4. PROSTQA Model–Predicted Probabilities of Men Having Functional Erections Suitable for Intercourse 2 Years After Brachytherapy for Prostate Cancer

<table>
<thead>
<tr>
<th>Age, y</th>
<th>Race/Ethnicitya</th>
<th>BMIb</th>
<th>67</th>
<th>83</th>
<th>100</th>
</tr>
</thead>
<tbody>
<tr>
<td>60</td>
<td>African American</td>
<td>&lt;25</td>
<td>78</td>
<td>(48-94)</td>
<td>92</td>
</tr>
<tr>
<td></td>
<td></td>
<td>25-35</td>
<td>61</td>
<td>(35-83)</td>
<td>83</td>
</tr>
<tr>
<td></td>
<td></td>
<td>≥35</td>
<td>28</td>
<td>(7-69)</td>
<td>56</td>
</tr>
<tr>
<td>65</td>
<td>White/other</td>
<td>&lt;25</td>
<td>54</td>
<td>(33-74)</td>
<td>79</td>
</tr>
<tr>
<td></td>
<td></td>
<td>25-35</td>
<td>34</td>
<td>(22-48)</td>
<td>62</td>
</tr>
<tr>
<td></td>
<td></td>
<td>≥35</td>
<td>11</td>
<td>(3-37)</td>
<td>29</td>
</tr>
<tr>
<td>70</td>
<td>African American</td>
<td>&lt;25</td>
<td>73</td>
<td>(41-91)</td>
<td>89</td>
</tr>
<tr>
<td></td>
<td></td>
<td>25-35</td>
<td>54</td>
<td>(28-77)</td>
<td>79</td>
</tr>
<tr>
<td></td>
<td></td>
<td>≥35</td>
<td>22</td>
<td>(5-62)</td>
<td>48</td>
</tr>
<tr>
<td>75</td>
<td>White/other</td>
<td>&lt;25</td>
<td>46</td>
<td>(28-66)</td>
<td>73</td>
</tr>
<tr>
<td></td>
<td></td>
<td>25-35</td>
<td>27</td>
<td>(18-39)</td>
<td>54</td>
</tr>
<tr>
<td></td>
<td></td>
<td>≥35</td>
<td>9</td>
<td>(2-30)</td>
<td>23</td>
</tr>
</tbody>
</table>

**COMMENT**

Erectile dysfunction is a well-recognized consequence of primary prostate cancer treatment. Accurate prediction of this adverse sexual HRQOL outcome is pivotal to set appropriate expectations and facilitate medical decision-making. However, the ability to inform individual patients how likely they are to develop erectile dysfunction based on their personal baseline sexual function, cancer severity, individual clinical characteristics, and treatment plan has been elusive. Our findings address this need by providing a validated, broadly applicable framework to predict the probability of long-term, posttreatment erectile dysfunction for individual patients.

Stratifying posttreatment outcome by pretreatment sexual HRQOL has been limited to a few single-institution studies.22,23 Our findings extend to the multicenter setting the observed relationship of pretreatment baseline sexual HRQOL with posttreatment outcome. We had initially described the PROSTQA cohort in a report that characterized the time course of mean HRQOL score changes across multiple HRQOL domains and identified factors broadly associated with such changes from pretreatment baseline to posttreatment.
early follow-up. In the current study, we now expand on the prior report by developing models that predict erectile dysfunction based on individual factors; by extending the follow-up to focus on sexual outcome at a minimum of 2 years after treatment; by validating these predictive models in the external, community-based CaPSURE cohort to ascertain their generalizability; and by evaluating use of medications and devices by patients for erectile dysfunction. Moreover (and unlike in our prior report), the predictive models reported herein focus on a practical and clinically relevant dichotomous primary outcome—patient-reported ability of achieve erections firm enough for intercourse—based on response to question 26 on the EPIC-26 questionnaire, rather than evaluating total sexual HRQOL score as the end point. Our approach herein does use sexual HRQOL scores to quantify baseline status, but we focus on the end point of erections “firm enough for intercourse” to provide a concrete metric having practical relevance to routine clinical care.

The use and effectiveness of medications or devices for improving erections was previously limited to a few single-institution studies and a claims-based report. Medications and devices to assist with erectile function were used by slightly more than one-half of men in our study and were used more commonly among patients after prostatectomy, as was also noted in 2 single-institution studies. Phosphodiesterase 5 inhibitors were the most commonly used treatment for erectile dysfunction. Intracorporal penile injections were the most effective (helpful in 74% of those who tried them) but were the least used, perhaps owing to inconvenience or discomfort. The sparse use of mechanical devices (eg, vacuum erection device), particularly after external radiotherapy, suggests an underused approach to mitigating erectile dysfunction among prostate cancer survivors.

Our observation that baseline PSA level is associated with erectile function outcome after prostatectomy or external radiotherapy has not been previously described. Patients with higher PSA levels may have more extensive primary cancers or larger prostates that can affect surgical approach, even among those undergoing nerve-sparing surgery; 1 single-institution study showed a trend for inverse association of PSA level and erectile function following radical prostatectomy (univariable \( P = .06 \)) and a significant association of lower PSA level with greater nerve preservation (\( P <.001 \)). Prior studies have linked larger prostate size with worse postoperative erectile function, and larger prostate size is associated with higher serum PSA levels; we did observe a marginal association of prostate size with sexual outcome. Higher PSA levels can reflect greater cancer severity that may temer the extent of nerve sparing during prostatectomy or lead to broader distribution of higher radiotherapy doses during treatment planning. The concurrent association of larger prostate size as well as of greater cancer severity with higher serum PSA level may be the basis for the association that we observed between pretreatment PSA levels and posttreatment sexual outcome.

Although our study revealed poorer recovery of erectile function with increasing number of comorbid conditions in univariable analyses, these were not significant on multivariate analysis. Other researchers have found diabetes and peripheral vascular disease to be associated with worse posttreatment sexual outcome; however, those studies did not adjust for differences in pretreatment sexual function. The lack

### Table 5. Calibration of PROSTQA Models in the CaPSURE Cohort: Comparison of Model-Predicted Probabilities of Functional Erections Suitable for Intercourse to Observed Proportions of Men Reporting Functional Erections 2 Years After Treatment

<table>
<thead>
<tr>
<th>Quintiles (Ranges) of PROSTQA Model–Predicted Probabilities</th>
<th>Functional Erections 2 y After Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Observed Proportion</td>
</tr>
<tr>
<td>Prostatectomy</td>
<td></td>
</tr>
<tr>
<td>1st (0.001-0.030)</td>
<td>0.01</td>
</tr>
<tr>
<td>2nd (0.031-0.114)</td>
<td>0.07</td>
</tr>
<tr>
<td>3rd (0.115-0.246)</td>
<td>0.18</td>
</tr>
<tr>
<td>4th (0.247-0.403)</td>
<td>0.32</td>
</tr>
<tr>
<td>5th (0.404-0.760)</td>
<td>0.52</td>
</tr>
<tr>
<td>All</td>
<td>0.22</td>
</tr>
<tr>
<td>External radiotherapy</td>
<td></td>
</tr>
<tr>
<td>1st (0.005-0.013)</td>
<td>0.01</td>
</tr>
<tr>
<td>2nd (0.014-0.031)</td>
<td>0.02</td>
</tr>
<tr>
<td>3rd (0.032-0.089)</td>
<td>0.05</td>
</tr>
<tr>
<td>4th (0.089-0.251)</td>
<td>0.16</td>
</tr>
<tr>
<td>5th (0.252-0.789)</td>
<td>0.43</td>
</tr>
<tr>
<td>All</td>
<td>0.13</td>
</tr>
<tr>
<td>Brachytherapy</td>
<td></td>
</tr>
<tr>
<td>1st (0.005-0.006)</td>
<td>0.003</td>
</tr>
<tr>
<td>2nd (0.007-0.035)</td>
<td>0.02</td>
</tr>
<tr>
<td>3rd (0.036-0.148)</td>
<td>0.09</td>
</tr>
<tr>
<td>4th (0.149-0.469)</td>
<td>0.30</td>
</tr>
<tr>
<td>5th (0.470-0.950)</td>
<td>0.68</td>
</tr>
<tr>
<td>All</td>
<td>0.22</td>
</tr>
</tbody>
</table>

**Table 5.** Calibration of PROSTQA Models in the CaPSURE Cohort: Comparison of Model-Predicted Probabilities of Functional Erections Suitable for Intercourse to Observed Proportions of Men Reporting Functional Erections 2 Years After Treatment

**Abbreviations:** CaPSURE, Cancer of the Prostate Strategic Urologic Research Endeavor; PROSTQA, Prostate Cancer Outcomes and Satisfaction With Treatment Quality Assessment.

- **Characteristics that differed between CaPSURE respondents and nonrespondents included race/ethnicity, relationship status, education, Gleason score at biopsy, and nerve sparing. Calibration was assessed within quintiles (fifths) of the distribution of model-predicted probabilities.
- Individual model-predicted probabilities were calculated using the inverse logistic function \( \hat{p} = \frac{1}{1 + e^{X\beta}} \), where \( X \) is the sum with \( X \) representing individual characteristics observed and \( \beta \) representing the associated model parameter estimates for the individual characteristics in Table 1.

©2011 American Medical Association. All rights reserved.
of significance of comorbid conditions in our multivariable analyses may be attributable, in part, to comorbid conditions influencing the sexual HRQOL score at baseline (comorbidity in the PROSTQA cohort was significantly correlated with pretreatment sexual HRQOL score; Spearman r = −0.31), whereby baseline sexual HRQOL score effect may supercede concurrent effects of comorbidity on posttreatment sexual outcome.

Consistent with prior reports, expected benefits of nerve sparing during prostatectomy,10,13,31,34 and detractors associated with use of adjuvant androgen-suppressive therapy during radiation35 were observed in our study, wherein the nerve-sparing benefit was extended to an intent-to-treat analysis. Our predictive models further extend the characterization of these treatment modifications by indicating how their effects can be mitigated by other factors, such as poor sexual functioning at baseline (as reflected by lower EPIC-26 sexual HRQOL score) or high pretreatment PSA level. Some features of the predictive models have broad confidence intervals because of relatively small numbers, but our internal assessment of model overfitting confirmed robustness of the contribution of the factors, and consideration of clinical relevance (eg, nerve-sparing vs non–nerve-sparing surgical techniques) maintained the factors in the models.

Of interest, the models were more accurate in predicting erections following external radiotherapy than those following prostatectomy (AUCs of 0.77 [95% CI, 0.74–0.80] for prostatectomy, 0.87 [95% CI, 0.80–0.94] for external radiotherapy, and 0.90 [95% CI, 0.85–0.93] for brachytherapy). In an exploratory analysis, we did not detect any association between prostatectomy volume at individual centers and sexual HRQOL outcome (correlation r = 0.04, P = .17), suggesting that treatment proficiency is not attributable simply to individual center treatment volume. Whether factors such as surgeon proficiency or unmeasured factors (eg, variations in specific surgical techniques) contribute to the broader range of outcomes we observed after prostatectomy warrants further study.

Limitations of our study are related to its observational design, introducing the possibility of selection bias by treatment. Therefore, our predictions of erectile function are best suited to guide outcome expectations within treatment groups based on individual patient characteristics and do not provide conclusive evidence of treatment superiority. Our focus on a time of 2 years after treatment for these analyses does not discern effects of baseline factors on the dynamics of erection recovery (eg, after prostatectomy) or deterioration (eg, after radiotherapy); however, we selected this point as a focal point of long-term outcomes based on prospective studies suggesting relative stabilization of sexual HRQOL changes at 2 to 3 years following treatment, although there may be some potential for continued improvement and deterioration of sexual function following prostatectomy and radiotherapy, respectively, even after 2 years.36,37

The HRQOL instruments used to measure baseline sexual function in the development cohort (EPIC-26) and validation cohort (UCLA-PCI) were not identical; nevertheless, both instruments contain the question regarding...
whether erections are firm enough for intercourse, which is the principal end point of the predictive models, and correlation of sexual function scores between the EPIC-26 and the UCLA-PCI have been shown to be highly correlated when both of these questionnaires were administered to the same patients in other studies. Measuring sexual HRQOL at the point of care with the EPIC-26 may be cumbersome and could impede use of our findings in routine practice. To address this barrier (separately from this study), we have developed the EPIC for Clinical Practice, a one-page HRQOL questionnaire that can be completed in 5 minutes and allows HRQOL scores to be easily calculated by clinicians at the point of care.

Last, our study did not evaluate the usage or possible effects of erectile re habilitation regimens, nor did the models control for use of medications or devices (that we instead reported as a concurrent consequence of erectile dysfunction). Nevertheless, our model validation in the external PROSTQA cohort indicates that this predictive model is generalizable despite these limitations.

We have developed clinically applicable models to predict recovery of erectile function following prostatectomy, external radiotherapy, or brachytherapy for early-stage prostate cancer based on pretreatment sexual function, patient characteristics, and specific plan of treatment. External validation of this predictive model in a community-based cohort suggests that these findings are generalizable and may help physicians and patients to set personalized expectations regarding prospects for erectile function in the years following primary treatment for prostate cancer.

Author Affiliations: Urology Division (Dr Alemozaffar and Sanda) and Radiation Oncology Department (Dr Kaplan), Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute and Harvard Medical School (Dr Regan); Department of Urology, University of Michigan, Ann Arbor; Department of Radiation Oncology, Cedars-Sinai Medical Center, Los Angeles; Cancer and Radiation Oncology, University of Washington, Seattle; Department of Biostatistics (Dr Sanda), Office for Survey Research and Institute for Public Policy and Social Research, Michigan State University, East Lansing (Dr Hembrow); Departments of Urology (Dr Saigal and Litwin) and Health Services (Dr Litwin), UCLA Center for Health Sciences, Los Angeles; Glickman Urological and Kidney Institute (Dr Klein) and Department of Radiation Oncology (Dr Ciezki), Cleveland Clinic Hospitals, Cleveland, Ohio, and Ohio State University Comprehensive Cancer Center, Columbus; Departments of Radiation (Dr Pisters) and Radiation Oncology (Dr Kuban), M.D. Anderson Cancer Center, Houston, Texas.

Author Contributions: Dr Sanda had full access to all data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Drs Alemozaffar and Regan contributed equally as first authors. Drs Cooperberg and Wei contributed equally as co-senior authors. Drs Carroll and Sanda shared senior authorship.

Study concept and design: Alemozaffar, Regan, Wei, Michalski, Hembrow, Saigal, Litwin, Klein, Wood, Carroll, Sanda. Acquisition of data: Cooperberg, Wei, Michalski, Sander, Hembrow, Saigal, Litwin, Klein, Kibel, Hamstra, Pisters, Kuban, Kaplan, Wood, Ciezki, Carroll, Sanda. Analysis and interpretation of data: Regan, Cooperberg, Michalski, Sander, Sadetsky, Saigal, Litwin, Klein, Pisters, Wood, Dunn, Carroll, Sanda. Drafting of the manuscript: Alemozaffar, Regan, Cooperberg, Hamilton, Hembrow, Kaplan, Snda. Critical revision of the manuscript for important intellectual content: Regan, Cooperberg, Wei, Michalski, Sander, Hembrow, Sadetsky, Saigal, Litwin, Klein, Kibel, Hamstra, Pisters, Kuban, Kaplan, Wood, Ciezki, Dunn, Carroll, Sanda. Statistical analysis: Alemozaffar, Regan, Sadetsky, Dunn.

Obtained funding: Saigal, Kibel, Carroll, Sanda. Administrative, technical, or material support: Wei, Michalski, Hembrow, Saigal, Litwin, Klein, Kibel, Hamstra, Pisters, Wood, Ciezki, Carroll, Sanda. Study supervision: Hembrow, Kuban, Carroll, Sanda.

Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. None of the coauthors have been compensated specifically for work related to this manuscript; however, several have received research support from the National Institutes of Health (NIH) to cover costs of conducting the study. Dr Cooperberg reported serving as a consultant for Denon and Oncotype DX; receiving payment for lectures from Takeda, Abbott, and Amgen. Dr Wei reported serving as a consultant for Envisioneer Inc and sanofi-aventis; serving as an expert witness for Genprobe; serving as a proctor for American Medical Systems; and receiving research funding from sanofi-aventis. Dr Michalski reported making donations to charity in lieu of honoraria for his role as a board member of Jill Hardy, BS (University of California, San Francisco), for analytic support. The individuals and the coordinators at each clinical site participated as research study staff but were not compensated specifically for this manuscript.

Funding/Support: The study was supported by NIH grants 1R01 CA 56562 and 1R01-CA 95662.

Role of Sponsor: The NIH had no role in the design and conduct of the study; the collection, management, analysis, and interpretation of the data; or the preparation, review, or approval of the manuscript.

Online Only Material: eTables 1-4 and Author Interview are available at http://www.jama.com.

Additional Contributions: We acknowledge the help of Jill Hardy, MS (Michigan State University), Beth Doiron, BA (Beth Israel Deaconess Medical Center), and Catrina Crociani, MPH (Beth Israel Deaconess Medical Center), for project management; and Alemozaffar, BS (University of California, San Francisco), for analytic support. The individuals and the coordinators at each clinical site participated as research study staff but were not compensated specifically for this manuscript.

REFERENCES


PREDICTING ERECTILE FUNCTION AFTER PROSTATE CANCER